Sorrento Therapeutics Profit Margin

Sorrento Therapeutics (SRNE) currently reports a profit margin of -8.31% as of June 2023. That compares with -9.55% in the prior-year period — up 13.0% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Sorrento Therapeutics's profit margin history and peer comparisons.

Sorrento Therapeutics's profit margin increased from -9.55% to -8.31% — a 13.0% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sorrento Therapeutics's profit margin of -8.31% is lower than the Healthcare sector average of 15.58%. That is roughly 5433.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sorrento Therapeutics's current -8.31% should be judged against Healthcare norms (sector average: 15.58%) and against SRNE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -8.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Sorrento Therapeutics, and consider following SRNE for alerts when major investors trade the stock.